Related Experiment Videos
Coronary artery stent placement with postprocedural antiplatelet therapy in acute myocardial infarction
H Walter1, F J Neumann, M Hadamitzky
1Deutsches Herzzentrum, München, Germany. walterh@dhm.mhn.de
Insights
Coronary stenting for acute myocardial infarction (AMI) is safe and effective with antiplatelet therapy. This study shows favorable short- and long-term outcomes in patients undergoing stent placement for AMI.
Area of Science:
- Cardiology
- Interventional Cardiology
- Acute Myocardial Infarction Research
Background:
- Coronary artery stent implantation in acute myocardial infarction (AMI) has demonstrated feasibility and safety with antiplatelet therapy.
- Previous validation in large cohorts was lacking.
- This observational study aimed to investigate outcomes in a significant patient group.
Purpose of the Study:
- To evaluate the outcomes of coronary stenting in patients with acute myocardial infarction.
- To assess the safety and efficacy of combined antiplatelet therapy post-stenting.
- To validate coronary stenting in AMI within a larger patient cohort.
Main Methods:
- Observational study of 318 consecutive patients with AMI undergoing infarct artery stent placement.
- Patients received combined antiplatelet therapy (aspirin and ticlopidine).
- Follow-up included clinical assessment, repeat interventions, and quantitative angiography.
Main Results:
- A low rate of cardiac events (6.6%) within 30 days, including cardiac death (1.6%) and re-infarction (1.3%).
- A high 6-month survival rate (94.7%) free of repeat AMI.
- A 25% binary restenosis rate at 6-month angiography.
Conclusions:
- Coronary stenting in AMI, coupled with postprocedural antiplatelet therapy, leads to favorable short-term and long-term results.
- The findings support the use of coronary stenting as a viable treatment option for AMI.
- Effective antiplatelet regimens are crucial for optimal outcomes in stented AMI patients.
Background:
We have shown that coronary artery stent implantation in acute myocardial infarction (AMI) is feasible and safe when combined with effective postprocedural antiplatelet therapy. However, the concept of coronary stenting in AMI has not been validated in large cohorts. In this observational study, we investigated the outcome in 318 consecutive patients.
Methods And Results:
From January 1995 until December 1996, 420 of 455 (92.3%) patients admitted to our institutions with AMI underwent infarct artery stent placement. This report describes the 318 patients treated with combined antiplatelet therapy whose AMI was not complicated by cardiogenic shock or mechanical ventilation before the intervention. Postinterventional therapy consisted of 100 mg aspirin and 250 mg ticlopidine twice daily. There were 21 (6.6%) cardiac events during 30-day follow-up: five cardiac deaths (1.6%), four nonfatal re-infarctions (1.3%) and 13 target vessel revascularizations (4.1%). Six months of clinical follow-up yielded a 94.7% survival rate free of repeat AMI. The rate of repeat interventions was 11%. Quantitative computerized angiography at 6 months, performed in 79.4% of the eligible patients, revealed a binary restenosis rate of 25%.
Conclusions:
With postprocedural antiplatelet therapy, coronary stenting in AMI yields favorable short- and long-term outcomes.